Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Pushing Stones Uphill: Why Patients Are Lost to Follow-Up After Uncomplicated Ureteroscopy.

Brooks NA, Paul CJ, Ghareeb GM, Tracy CR.

J Endourol. 2017 Feb;31(2):135-140. doi: 10.1089/end.2016.0675.

PMID:
28049356
2.

Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.

Steinberg RL, Brooks NA, Thomas LJ, Mott SL, O'Donnell MA.

Urol Oncol. 2016 Dec 29. pii: S1078-1439(16)30404-5. doi: 10.1016/j.urolonc.2016.11.016. [Epub ahead of print]

PMID:
28041998
3.

Treatment options in non-muscle-invasive bladder cancer after BCG failure.

Brooks NA, O'Donnell MA.

Indian J Urol. 2015 Oct-Dec;31(4):312-9. doi: 10.4103/0970-1591.166475. Review.

4.

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y, Ye XS.

Mol Cancer Ther. 2014 Feb;13(2):364-74. doi: 10.1158/1535-7163.MCT-13-0513.

5.

Mohs micrographic surgery for the treatment of melanoma.

Hui AM, Jacobson M, Markowitz O, Brooks NA, Siegel DM.

Dermatol Clin. 2012 Jul;30(3):503-15. doi: 10.1016/j.det.2012.04.010. Review.

PMID:
22800554
6.

Three-minute chemosurgical biopsy site treatment for invasive cutaneous melanoma.

Brooks NA.

Dermatol Surg. 2012 Jun;38(6):968-9. doi: 10.1111/j.1524-4725.2012.02411.x. No abstract available.

PMID:
22642459
7.

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.

Bradbury RH, Hales NJ, Rabow AA, Walker GE, Acton DG, Andrews DM, Ballard P, Brooks NA, Colclough N, Girdwood A, Hancox UJ, Jones O, Jude D, Loddick SA, Mortlock AA.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5442-5. doi: 10.1016/j.bmcl.2011.06.122.

PMID:
21782422
8.

Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors.

Wang Z, Watt W, Brooks NA, Harris MS, Urban J, Boatman D, McMillan M, Kahn M, Heinrikson RL, Finzel BC, Wittwer AJ, Blinn J, Kamtekar S, Tomasselli AG.

Biochim Biophys Acta. 2010 Sep;1804(9):1817-31. doi: 10.1016/j.bbapap.2010.05.007.

PMID:
20580860
9.

A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice.

Brooks NA, Pouniotis DS, Sheng KC, Apostolopoulos V, Pietersz GA.

Biochim Biophys Acta. 2010 Dec;1798(12):2286-95. doi: 10.1016/j.bbamem.2010.05.007.

10.

Chemosurgery for invasive melanoma.

Brooks NA.

Dermatol Surg. 2010 Feb;36(2):237-40. doi: 10.1111/j.1524-4725.2009.01397.x. No abstract available.

PMID:
20039917
11.

Cell-penetrating peptides: application in vaccine delivery.

Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA.

Biochim Biophys Acta. 2010 Jan;1805(1):25-34. doi: 10.1016/j.bbcan.2009.09.004. Review.

PMID:
19782720
12.

IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.

Staschke KA, Dong S, Saha J, Zhao J, Brooks NA, Hepburn DL, Xia J, Gulen MF, Kang Z, Altuntas CZ, Tuohy VK, Gilmour R, Li X, Na S.

J Immunol. 2009 Jul 1;183(1):568-77. doi: 10.4049/jimmunol.0802361.

13.

Type 2 diabetes: lifestyle changes and drug treatment.

Brooks NA.

Virtual Mentor. 2009 Mar 1;11(3):237-41. doi: 10.1001/virtualmentor.2009.11.3.cprl1-0903. No abstract available.

14.

Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content.

Brooks NA, Wilcox G, Walker KZ, Ashton JF, Cox MB, Stojanovska L.

Menopause. 2008 Nov-Dec;15(6):1157-62. doi: 10.1097/gme.0b013e3181732953.

PMID:
18784609
15.

Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine.

Azzopardi TD, Brooks NA.

Ann Pharmacother. 2008 Mar;42(3):397-402. doi: 10.1345/aph.1K481. Review.

PMID:
18285561
16.

Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers.

Gregson SJ, Howard PW, Gullick DR, Hamaguchi A, Corcoran KE, Brooks NA, Hartley JA, Jenkins TC, Patel S, Guille MJ, Thurston DE.

J Med Chem. 2004 Feb 26;47(5):1161-74.

PMID:
14971896
17.

Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE.

J Med Chem. 2001 Mar 1;44(5):737-48.

PMID:
11262084
18.
19.
20.

Users' responses to assistive devices for physical disability.

Brooks NA.

Soc Sci Med. 1991;32(12):1417-24.

PMID:
1831289
Items per page

Supplemental Content

Loading ...
Support Center